Skip to content
Open access

Distinct iron metabolism regulation during cachexia progression in murine models of intestinal and pancreatic cancer

Oct 2026 · bioRxiv · 0 citations · 40 references
Biology

TL;DR

Findings reveal cancer type-specific signatures of iron regulation in cachexia, which appear to be more driven by cancer type specific features than by cachexia severity itself, with skeletal muscle iron metabolism impaired mainly when cachexia is associated with anemia.

Abstract

Background Cancer cachexia is a multifactorial syndrome characterized by substantial metabolic disturbances including systemic inflammation, and muscle atrophy, which may affect the regulation of iron metabolism in patients. This study aimed to characterize this regulation in two murine models of colorectal and pancreatic cancer, both associated with a high prevalence of cachexia. Methods Histological, biochemical and molecular analyses were performed in serum, skeletal muscle, liver, spleen and tumor from UN-KC-6141 pancreatic tumor bearing mice and from ApcMin/+ mice (colorectal cancer model), both models exhibiting variable cachexia severity. Results Both models induce cachexia, but diverge markedly in their regulation of iron metabolism. UNKC mice display reduced plasma iron availability (-9.6% transferrin saturation, p<0.001) without concomitant anemia, while hepatic hepcidin synthesis is upregulated (+100.6%, p<0.001) by inflammation, promoting ferroportin (FPN) downregulation (-42.4%, p<0.001) and iron sequestration in the spleen (+134% total iron content, p<0.001). In the atrophied gastrocnemius, iron concentration is preserved through increased ferritin (+86.6%, p=0.010) and hemoproteins (i.e., myoglobin, CYSC, COXIV) expression. Conversely, ApcMin/+ mice exhibit anemia together with hepatic and splenic iron depletion (-48.4%, p<0.001 and - 84.9%, p<0.001, respectively). Hepcidin synthesis is downregulated (-99.9%, p<0.001) despite persistent inflammation, indicating that hypoxia and/or iron-deficiency signals probably predominate over the inflammatory pathway. FPN is markedly decreased (-94.2%, p<0.001) in the iron-depleted spleen despite low hepcidin. In the atrophied quadriceps of ApcMin/+ mice, iron deficiency is associated with decreased FPN and ferritin (-87.9%, p<0.001, and -38.4%, p=0.016, respectively), and increased TfR1 expression (+305%, p=0.107). Finally, tumor iron import may play a significant role in cachexia progression, as suggested by the association between tumor weight, tumor TfR1 protein levels and body weight loss in UNKC mice. Conclusion These findings reveal cancer type-specific signatures of iron regulation in cachexia, which appear to be more driven by cancer type specific features than by cachexia severity itself, with skeletal muscle iron metabolism impaired mainly when cachexia is associated with anemia. This suggests that the clinical management of iron metabolism in cachectic patients should be guided by the underlying cancer type. Abstract figure legend Cancer cachexia is associated with iron redistribution, diverging between UN-KC-6141 pancreatic cancer model and the ApcMin/+ colorectal cancer model. In pancreatic cancer, hepatic hepcidin is upregulated, likely in response to inflammation, and induces splenic iron sequestration, resulting in decreased plasma iron availability. In colorectal cancer, cachexia is associated with anemia together with splenic and hepatic iron depletion, whose signals probably drive hepcidin downregulation despite inflammation. Whatever the model, skeletal muscle appears to engage cellular adaptive regulatory mechanisms to preserve itself from the systemic iron dysregulation induced by cancer cachexia and its associated features.

Read PDF

Similar papers

Open access Sep 2026

Furan fatty acid supplementation protects against muscle atrophy during cancer cachexia

Background Cachexia is a multifactorial syndrome frequently observed in cancer patients, characterized by progressive weight loss, muscle atrophy, and systemic inflammation. We recently demonstrated that supplementation with FuFA-F2, a naturally occurring lipid found in various foods, increases muscle mass in different...

Anaïs Deglos, Jennifer Falconi, Charles Géminard et al. · 0 citations
Open access Sep 2026

An iron-regulated methionine redox axis governs adipose browning and cancer cachexia.

Adipose browning and atrophy are early events of cachexia, a lethal metabolic disorder affecting nearly half of the population with cancer. Here, using individual-derived specimens and mouse models, we identified an iron-dependent pathway that initiates adipose browning in both physiological and cachectic settings. Upo...

Jung Seung Nam, Sung Shin Ahn, Yeonoh Shin et al. · 1 citation
Review Open access Sep 2026

Cancer Cachexia in Advanced Renal Cell Carcinoma: From Molecular Mechanisms to Prognostic Assessment

Preclinical and emerging clinical data suggest that targeted therapies may partially attenuate cachexia by modulating inflammatory signaling, while multimodal interventions integrating nutritional support and exercise rehabilitation remain the cornerstone of management.

Yu-Shuang Cui, Yu-Dong Cao, Chen Lin et al. · 0 citations
Open access Sep 2026

Ferroptosis regulates metabolic inflammation-driven tumorigenesis in obesity-related gastric cancer.

Cotreatment with HFD and GSK may promote SCJ tumor progression by suppressing ferroptosis through intratumoral NRF2 signaling and dysbiosis-related metabolites, indicating a negative role of PPAR-δ signaling on MetS-related SCJ tumorigenesis.

Mizuki Tanabe, K. Uno, Toru Tamahara et al. · 0 citations
Review Open access Oct 2026

Beyond reduced intake: tumor metabolism and immune dysregulation drive cancer-related malnutrition in head and neck squamous cell carcinoma (HNSCC)

Cancer-related malnutrition is highly prevalent in patients with head and neck squamous cell carcinoma (HNSCC) and represents a major determinant of treatment tolerance, quality of life, and survival. Although traditionally attributed to reduced oral intake caused by dysphagia, mucositis, and treatment-related toxicity...

V. Zurlo, Arianna Piccirillo, M. L. Marciano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.